We envisage that the evidence collected in this study will be utilized to develop a specific antagonist of VPS4A which can be administered from the start of chemotherapy with Oxa to prevent tumor cells becoming resistant to the drug and improve the chances of success with it. This evidence concerns the gene VPS4A and neoplasm.